SCHEMBL7165264

SCHEMBL7165264

O=C1Cc2ccccc2N1c1c(Cl)cc(O)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.53
KMT2A Q03164 4/20 0.48
GAA P10253 4/20 0.48
MEN1 O00255 3/20 0.48
NOTUM Q6P988 1/20 0.46
CASP6 P55212 4/20 0.44
MAPK14 Q16539 2/20 0.40
CASP3 P42574 2/20 0.39
SENP8 Q96LD8 2/20 0.39
SENP7 Q9BQF6 2/20 0.39
SENP6 Q9GZR1 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
GRM1 Q13255 1/20 0.37
SPR P35270 1/20 0.36
PKM P14618 1/20 0.36
TLR9 Q9NR96 1/20 0.36
MAPT P10636 1/20 0.36
ALOX12 P18054 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651988 0.84 GAA (0.59) HPGDKMT2AGAAMEN1NOTUM
SCHEMBL2982634 0.84 GAA (0.59) HPGDKMT2AGAAMEN1NOTUM
SCHEMBL9525943 0.79 MEN1 (0.65) HPGDKMT2AGAAMEN1CASP6
SCHEMBL11133610 0.77 HPGD (0.62) HPGDKMT2AGAAMEN1NOTUM
SCHEMBL11563122 0.75 HPGD (0.51) HPGDKMT2AGAAMEN1NOTUM
SCHEMBL4463146 0.74 HPGD (0.74) HPGDKMT2AGAAMEN1NOTUM
SCHEMBL4692980 0.74 HPGD (0.69) HPGDKMT2AGAAMEN1NOTUM
SCHEMBL7167602 0.74 HPGD (0.50) HPGDKMT2AGAAMEN1NOTUM
SCHEMBL7845228 0.73 HPGD (0.57) HPGDKMT2AGAAMEN1NOTUM
SCHEMBL7845153 0.73 KMT2A (0.53) HPGDKMT2AGAAMEN1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552077-B2 Kidney disorders EXOCELL, INC. 2003-04-22 US disclosed
EP-1242069-A2 ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES EXOCELL, INC. (US) 2002-09-25 EP disclosed
US-6355680-B1 BLOCKING REACTION OF GLUCOSE AND ALBUMIN EXOCELL, INC. 2002-03-12 US disclosed
US-20010034359-A1 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies EXOCELL, INC. 2001-10-25 US disclosed
WO-2001003684-A2 ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES EXOCELL, INC. (US) 2001-01-18 WO disclosed
US-5159085-A Antiinflammatory, antiallergens, cytoprotective agents AMERICAN HOME PRODUCTS CORPORATION (US) 1992-10-27 US disclosed
US-5021576-A Antiinflammatory, antiarthritic, hypotensive, anticarcinogenic agents AMERICAN HOME PRODUCTS CORPORATION (US) 1991-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034359-A1 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies ALB, AGER, TTR HPGD 1845/4885KMT2A 4772/4885GAA 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.